Clinical and pathological characteristics and prognosis of 132 cases of rectal neuroendocrine tumors

Table 1 Single factor COX regression analysis

		B	SE	Wald	df	P value	RR	95%CI
Age (yr)	< 55	0.847	0.458	3.415	1	0.065	2.332	0.950	5.723
	≥ 55
Gender	Male	0.850	0.429	3.918	1	0.048	2.340	1.008	5.429
	Female
Tumor size	< 2 cm	3.177	0.748	18.046	1	0.000	23.984	5.537	103.895
	≥ 2cm
Lymph node metastasis	No	2.290	0.480	22.743	1	0.000	9.878	3.854	25.320
	Yes
Distant metastasis	No	0.806	0.552	2.129	1	0.144	2.239	0.758	6.608
	Yes
Radical excision	No	-1.970	0.424	21.612	1	0.000	0.139	0.061	0.320
	Yes
Pathological grade	G1 + G2	2.648	0.630	17.657	1	0.000	14.121	4.107	48.552
	NEC
Syn	Negative	-0.295	0.547	0.291	1	0.589	0.744	0.255	2.175
	Positive
CgA	Negative	-0.049	0.456	0.012	1	0.914	0.952	0.389	2.326
	Positive

Syn: Synaptophysin; CgA: Chromogranin A; NEC: Neuroendocrine carcinoma.

Table 2 Multivariate COX regression analysis

	B	SE	Wald	df	P value	RR	95%CI
Gender	0.331	0.476	0.481	1	0.488	1.392	0.547	3.541
Tumor size	2.320	1.151	4.065	1	0.044	10.173	1.067	97.012
Lymph node metastasis	0.613	0.628	0.954	1	0.329	1.846	0.539	6.320
Radical excision	-0.581	0.488	1.416	1	0.234	0.559	0.215	1.456
Pathological grade	-0.048	1.009	0.002	1	0.962	0.953	0.132	6.889

Table 3 Difference in 5-year survival rate in 132 patients with neuroendocrine tumors by age, gender, tumor size, lymph node metastasis, distant metastasis, radical excision, pathological grade, and synaptophysin and chromogranin A expression

		n	5-yr survival rate	χ2	P value
Age (yr)	< 55	73	83.6	0.554	0.457
	≥ 55	59	88.1
Gender	Male	83	80.7	4.327	0.038
	Female	49	93.9
Tumor size	< 2 cm	105	98.1	64.98	0.000
	≥ 2cm	27	37
Lymph node metastasis	No	111	91.9	22.37	0.000
	Yes	21	52.4
Distant metastasis	No	127	86.6	2.765	0.096
	Yes	5	60
Radical excision	No	16	43.8	25.89	0.000
	Yes	116	91.4
Pathological grade	G1 + G2	104	99	71.79	0.000
	NEC	28	35.7
Syn	Negative	14	78.6	0.629	0.428
	Positive	118	86.4
CgA	Negative	80	83.8	0.568	0.451
	Positive	52	88.5

Syn: Synaptophysin; CgA: Chromogranin A; NEC: Neuroendocrine carcinoma.